Scarica l'app Stockscreener
2.90
4.92%
-0.15
Precedente Chiudi:
$3.05
Aprire:
$3.02
Volume 24 ore:
73,539
Relative Volume:
0.03
Capitalizzazione di mercato:
$35.56M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-10.49%
1M Prestazione:
+34.26%
6M Prestazione:
+72.62%
1 anno Prestazione:
-17.14%
Intervallo 1D:
$2.85
$3.069
Intervallo di 1 settimana:
$2.72
$3.37
Portata 52W:
$1.345
$6.3699
Q 32 Bio Inc Stock (QTTB) Company Profile
Nome
Q 32 Bio Inc
Settore
Industria
Telefono
781-999-0232
Indirizzo
830 WINTER STREET, WALTHAM
Confronta QTTB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
2.89 | 37.53M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.12 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
739.59 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.63 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
393.23 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.08 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | Raymond James | Strong Buy |
| 2024-09-11 | Iniziato | Wells Fargo | Overweight |
| 2024-06-17 | Iniziato | Guggenheim | Buy |
| 2024-05-21 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Oppenheimer | Outperform |
| 2024-04-02 | Iniziato | Piper Sandler | Overweight |
| 2023-07-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | Reiterato | BTIG Research | Neutral |
| 2022-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-02-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2020-12-14 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-24 | Iniziato | Chardan Capital Markets | Buy |
| 2019-11-01 | Iniziato | Oppenheimer | Perform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Q 32 Bio Inc Borsa (QTTB) Ultime notizie
Aug Technicals: Can Q32 Bio Inc stock attract ESG capital inflowsQuarterly Profit Review & Verified Momentum Stock Ideas - moha.gov.vn
Q32 Bio Insiders Benefit From Selling Stock At US$2.86 - simplywall.st
Stock Market Recap: Why millennials buy Spire Inc LGR stockInsider Buying & Safe Swing Trade Setups - BỘ NỘI VỤ
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Q32 Bio Inc. stock a defensive play in 2025Quarterly Profit Report & Accurate Technical Buy Alerts - Newser
Is Q32 Bio Inc. stock recession proofWeekly Profit Report & Technical Analysis for Trade Confirmation - Newser
Q32 Bio CEO Morrison sells $77870 in stock By Investing.com - Investing.com South Africa
Lee Kalowski, Q32 Bio CFO, sells $31k in shares By Investing.com - Investing.com South Africa
Insider Sell: Lee Kalowski Sells Shares of Q32 Bio Inc (QTTB) - GuruFocus
Lee Kalowski, Q32 Bio CFO, sells $31k in shares - Investing.com
CEO Morrison Sells 22,506 ($77.9K) Of Q32 Bio Inc [QTTB] - TradingView
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - MSN
Deal Watch: Akebia Gets Phase II Alopecia Areata Candidate From Cost-Conscious Q32 - Citeline News & Insights
Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M - MSN
Nothing is Better Than Q32 Bio Inc (QTTB) stock at the moment - Setenews
Block Trades: Will CGEN stock remain a Wall Street favorite2025 Technical Overview & Consistent Profit Alerts - BỘ NỘI VỤ
QTTB Stock Explodes Nearly 95%: Akebia Deal Transforms Q32 Bio’s Future - Bitget
Q32 Bio (QTTB) Stock Analysis Report | Financials & Insights - Benzinga
Will Q32 Bio Inc. stock attract ESG investorsTrade Analysis Report & Expert Verified Stock Movement Alerts - Newser
Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook - ts2.tech
Q32 Bio Sells Complement Inhibitor ADX-097 - citybiz
Q32 sells rare kidney disease drug to Akebia for $12M up front - BioWorld MedTech
Q32 Bio Inc. (QTTB) Stock: Jumps on Akebia Acquisition of ADX-097 and Extended Runway - parameter.io
QTTB Stock Surges: Market Insight - StocksToTrade
Dow Dips 200 Points; Q32 Bio Shares Jump - inkl
Why Is Small-Cap Q32 Bio Stock Soaring On Monday? - inkl
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal - marketscreener.com
Q32 Bio stock rockets after selling Phase 2 complement inhibitor to Akebia - Investing.com Nigeria
Q32 Bio sells complement inhibitor Adx-097 - marketscreener.com
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront - TipRanks
Akebia Therapeutics (AKBA) Acquires Phase 2 Drug from Q32 Bio - GuruFocus
Q32 Bio sells complement inhibitor ADX-097 to Akebia - TipRanks
Q32 Bio Sells ADX-097 to Akebia Therapeutics - TipRanks
Akebia Announces Establishment of Rare Kidney Disease Pipeline - The Manila Times
EBIT per share of Q32 Bio Inc – LSE:0T6G - TradingView
Cash per share of Q32 Bio Inc – LSE:0T6G - TradingView
Q32 Bio Inc.Common Stock (Nasdaq:QTTB) Stock Quote - Markets Financial Content
Form 8-KCurrent report - ADVFN
Layoff Tracker: Novartis Cuts 550 Employees as Swiss Manufacturing Priorities Shift - BioSpace
Q32 Bio Inc. Faces Financial Challenges Amid Development Efforts - MSN
What analysts say about Q32 Bio Inc stockEarnings Volatility Patterns & High Return Trading Plans - earlytimes.in
Q32 Bio Inc Stock Analysis and ForecastInstitutional Buying Trends & Small Entry Cost Portfolio - earlytimes.in
Q 32 Bio Inc Azioni (QTTB) Dati Finanziari
Non sono disponibili dati finanziari per Q 32 Bio Inc (QTTB). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Q 32 Bio Inc Azioni (QTTB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kalowski Lee | CFO and President |
Dec 02 '25 |
Sale |
3.46 |
9,072 |
31,395 |
39,938 |
0.42%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):